Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.

This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.

In this ongoing phase 3 study, ritlecitinib demonstrated sustained efficacy up to 24 months in patients aged 12 or older with alopecia areata, showing increased response rates with or without an initial loading dose and supporting its long-term use.

Deuruxolitinib is generally safe for treating alopecia areata.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

Ozenoxacin 1% cream is an effective and safe treatment for impetigo in children and adults.

This study reported that Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology significantly improved hair thickness, density, shine, and elasticity, while reducing hair loss by an average of 66.8% and enhancing hair growth by up to 32.5% in subjects with androgenic alopecia over nine months.

This study found that more than half of patients with severe alopecia areata who reduced their baricitinib dose from 4mg to 2mg maintained a clinical response for up to 2 years.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This phase 2 trial found that SM04554, a Wnt signaling modulator, was well-tolerated and increased follicle counts in males with androgenetic alopecia, suggesting potential for promoting hair growth.

In this study, topical CUR61414 was effective in inhibiting basal cell carcinomas in mice, but no clinical activity was observed in human trials.

In this study, brepocitinib was found to significantly reduce inflammatory biomarker CCL5 expression and improve clinical severity by week 24, while maintaining a favorable safety profile.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.

This study found that non-Caucasian patients are underrepresented in US RCTs for androgenetic alopecia, limiting the generalizability of the findings to the diverse general population.

This review discusses the current understanding of propranolol's use in treating infantile hemangiomas, covering its indications, effectiveness, side effects, and ongoing clinical trials, without presenting new clinical results.

In this study, aleglitazar and its metabolite M6 were evaluated for safety in non-clinical settings, revealing organ-targeting effects common to PPAR agonists but no significant tumor increase in rat carcinogenicity studies, supporting progression to Phase 3 clinical trials.

This study found that using 'moha: 5-in-1' hair oil for 8 weeks significantly reduced hair fall, increased hair growth rate and thickness, and decreased scalp dandruff among healthy adults with alopecia, with no adverse effects reported.

This paper discusses various factors influencing hair loss, highlighting hormonal imbalances as a key factor in androgenetic alopecia and proposing proteoglycan-containing drugs as promising treatments to promote hair growth and prolong the anagen phase.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.